Pfizer, GSK settle patent lawsuit over RSV vaccines

BeritK Pfizer ( NYSE: PFE ) and GSK ( NYSE: GSK ) on Thursday agreed to end a patent lawsuit over claims that the former’s vaccine, Abrysvo for respiratory syncytial virus (RSV) allegedly violated the British pharma giant’s patent rights related to its rival shot, Arexvy. Citing.